Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12832226 | 0.90 | CYP11B1 (0.46) | CYP11B1CYP11B2CRBNCHRM2CHRM3 | |
| SCHEMBL16189944 | 0.87 | — | — | |
| SCHEMBL21990818 | 0.86 | CYP11B1 (0.42) | CYP11B1CYP11B2CRBNCHRM2CHRM3 | |
| SCHEMBL21557329 | 0.85 | CHRM2 (0.42) | CYP11B1CYP11B2CRBNCHRM2CHRM3 | |
| SCHEMBL21557290 | 0.82 | BRD4 (0.40) | CYP11B1CYP11B2CRBNCHRM2CHRM3 | |
| SCHEMBL24186788 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2CRBNLRRK2 | |
| SCHEMBL17485296 | 0.81 | CYP11B1 (0.49) | CYP11B1CYP11B2CRBNCHRM2CHRM3 | |
| SCHEMBL9968466 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2CRBNCHRM2LRRK2 | |
| SCHEMBL12243268 | 0.81 | CYP11B1 (0.44) | CYP11B1CYP11B2CRBN | |
| SCHEMBL14359443 | 0.80 | CYP11B1 (0.43) | CYP11B1CYP11B2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3567030-B1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | MEDSHINE DISCOVERY INC. (CN) | 2021-06-22 | — | — | US | disclosed |
| EP-3792260-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3674291-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | Nippon Soda Co., Ltd. (JP) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | MEDSHINE DISCOVERY INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200163336-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2020-05-28 | — | — | US | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| EP-2630134-B9 | PYRIDINE-2- DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS | PFIZER (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9056865-B2 | Pyridine-2-derivatives as smoothened receptor modulators | PFIZER INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130210800-A1 | PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS | PFIZER INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013091507-A1 | HETEROCYCLE AMIDO ALKYLOXY SUBSTITUTED QUINAZOLINE DERIVATIVE AND USE THEREOF | QIAN WEI (CN) | 2013-06-27 | — | — | WO | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| WO-2011148962-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF | 大正製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040984-B2 | Quinazoline compound for EGFR inhibition | EGFR, ERBB2, ERBB4 | CYP11B1 3649/4885CYP11B2 3278/4885CRBN 3669/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | CYP11B1 84/4885CYP11B2 195/4885CRBN 3/4885 |
| US-20200190107-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | EGFR, ERBB2, ERBB4 | CYP11B1 3649/4885CYP11B2 3278/4885CRBN 3669/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | CYP11B1 25/4885CYP11B2 62/4885CRBN 3893/4885 |
| US-20200163336-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | H1-10, TAAR1, C5 | CYP11B1 2392/4885CYP11B2 2532/4885CRBN 2533/4885 |
| US-20130210800-A1 | PYRIDINE-2-DERIVATIVES AS SMOOTHENED RECEPTOR MODULATORS | SMO, EDNRB, RXFP1 | CYP11B1 1843/4885CYP11B2 1883/4885CRBN 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.